The Sensydia cardiac monitoring funding round gives a small medical technology company fresh money to take a noninvasive heart-assessment platform through a key clinical study and toward US regulatory authorisation. On 13 October 2026, Sensydia announced an oversubscribed initial closing of more than $6 million, led by Colle Capital Partners with substantial support from Orlando Health Ventures. The company will use the proceeds to carry its Cardiac Performance System (CPS) through a study called ACOUSTIC-1 and to prepare for commercial launch.
CPS is investigational. It is not authorised by the FDA, and the announcement gave no data on how well it works in the new study. Here is what the company says the system does, what regulatory and reimbursement milestones it has reached and what is still unknown.
Key takeaways
- Sensydia raised more than $6 million in an oversubscribed initial closing led by Colle Capital Partners.
- Funds will support the ACOUSTIC-1 study toward FDA authorisation and commercial launch preparation.
- CPS has FDA Breakthrough Device designation but remains investigational use only.
- A temporary billing code for noninvasive hemodynamic assessment took effect in July 2026.
- No details of the ACOUSTIC-1 design, size, endpoints or timeline were disclosed.
What the Sensydia cardiac monitoring funding will pay for
According to the company, the money will take CPS through ACOUSTIC-1, the study intended to support an FDA submission, and fund the groundwork for a commercial launch. The announcement does not give a budget breakdown, a valuation or the name of the round. It describes the financing as an initial closing, which implies more investment could follow. The company previously raised about $8 million in 2023, according to its earlier announcement.
The investors named are Colle Capital Partners and Orlando Health Ventures. Victoria Grace of Colle said the team built CPS on catheterisation data, the clinical gold standard, and that a billing code already in place gives confidence in the company.
How the Cardiac Performance System behind the Sensydia cardiac monitoring funding works
Sensydia describes CPS as a noninvasive platform that records acoustic and electrical signals from the chest and analyses them with artificial intelligence. The aim is to provide pulmonary pressure assessments in almost any clinical setting without the invasive catheter normally used to measure them. The company says the output could help identify fluid congestion and guide diagnosis and treatment in heart failure and pulmonary hypertension.
Heart failure is a condition in which the heart cannot pump enough blood for the body’s needs, and fluid build-up is a common cause of hospital admissions. The American Heart Association explains that managing fluid is central to treatment. If a noninvasive tool could reliably estimate pressures in the clinic or at the bedside, it could help doctors adjust treatment sooner. That depends on accuracy, which has not been shown publicly for this system.
Pulmonary hypertension, high blood pressure in the arteries of the lungs, is usually confirmed with a right-heart catheterisation, an invasive procedure done in specialist centres. A reliable noninvasive estimate could widen access to screening and follow-up, particularly outside large hospitals. It could also reduce repeated invasive tests for people who need regular monitoring. These are the company’s aims, and the evidence that the system can meet them is still to come.
Regulatory milestones behind the Sensydia cardiac monitoring funding
CPS has received Breakthrough Device designation from the FDA, a status that offers closer interaction with the agency for devices aimed at serious conditions. It does not mean the device is cleared or approved. The system is labelled investigational use only. The company’s earlier US clearance, granted in 2018, covered an algorithm that measures ejection fraction noninvasively, a different function from the pulmonary pressure assessment now in development.
The company also points to a Category III CPT code, 1036T, which took effect in July 2026 for noninvasive hemodynamic assessment. Category III codes are temporary codes for emerging technologies. They allow data collection on use, but they do not guarantee payment. The company says the code’s elements match its approach.
What we do not know beyond the Sensydia cardiac monitoring funding
- The design, size and endpoints of ACOUSTIC-1.
- How CPS pressure estimates compare with catheter measurements in patients.
- The planned FDA pathway and submission timing.
- Pricing, launch timing and who would pay for the test.
Gaps like these are normal at this stage of a device’s development, but they mean readers should treat the company’s description of CPS as a plan and not as a demonstrated result. Visit Sensydia for the company’s own description. For other cardiac technology stories, see our report on UK providers expanding minimally invasive cardiac care and our report on Imricor’s interventional MRI portfolio, or browse our medical device coverage.
Our assessment of the Sensydia cardiac monitoring funding
In our assessment, the Sensydia cardiac monitoring funding is a modest but sensible step for a company with a clear regulatory plan. Raising an initial $6 million with Breakthrough designation and a billing code in place reduces some of the usual commercial risk. The scientific risk remains. The core claim is that signals recorded at the skin can stand in for invasive pressure measurements, and the field has seen many noninvasive tools that struggled to match catheter accuracy across diverse patients. The ACOUSTIC-1 results will therefore matter more than the financing.
What to watch after the Sensydia cardiac monitoring funding
- Disclosure of the ACOUSTIC-1 protocol and enrolment.
- Further closings of the financing round.
- A pre-submission or submission to the FDA.
- Peer-reviewed accuracy data against catheterisation.
Frequently asked questions about the Sensydia cardiac monitoring funding
How big is the Sensydia cardiac monitoring funding?
More than $6 million in an oversubscribed initial closing, led by Colle Capital Partners.
What is the Cardiac Performance System?
A noninvasive platform that analyses acoustic and electrical signals with AI to assess pulmonary pressures, aimed at heart failure and pulmonary hypertension.
Is CPS approved by the FDA?
No. It has Breakthrough Device designation but is investigational use only.
What is ACOUSTIC-1?
The study that the funding will help complete toward FDA authorisation. Its design has not been disclosed.
Does the Sensydia cardiac monitoring funding show the device works?
No. Funding shows investor confidence, not clinical performance.
How we reported this: we relied on Sensydia’s 13 October 2026 announcement, which is a company statement. Last updated: 14 October 2026. This article is news reporting and not medical advice.
